Ligand Pharmaceuticals Projects Robust Royalty Revenue Growth by 2029

Published 10 hours agoLGND

Ligand Pharmaceuticals Projects Robust Royalty Revenue Growth by 2029

Ligand Pharmaceuticals has shared an ambitious financial outlook, revealing plans for a compound annual growth rate of at least 22% in royalty revenues through 2029. The company aims to achieve approximately $285 million in royalty receipts by that year, according to Nasdaq.com. This projection is part of a broader strategy that includes leveraging its research and development investments and technology platforms such as Captisol® and NITRICIL™.

In its 2025 financial guidance, Ligand expects total revenues to range between $180 million and $200 million, with royalty revenues contributing $135 million to $140 million. The company is also forecasting $35 million to $40 million in Captisol sales and $10 million to $20 million in contract revenue. For adjusted earnings per share, Ligand has set a target of $6.00 to $6.25. Nasdaq.com notes that key commercial programs like Filspari and Veklury are among those projected to drive this growth.

Recent strategic initiatives include significant investments totaling $192 million in the past two years across eight ventures, alongside evaluating over $1 billion in potential opportunities. Ligand Pharmaceuticals is focused on expanding its royalty portfolio and exploiting its technological platforms to secure substantial revenue growth in the coming years. By capitalizing on existing and emerging collaborations, the company aims to enhance its market position significantly.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Clean Energy Fuels Expands RNG Sales and Prepares for Cummins X15N Engine Launch

Clean Energy Fuels Expands RNG Sales and Prepares for Cummins X15N Engine Launch

3 minutes agoCLNE

Clean Energy Fuels Corp. recently reported significant growth in renewable natural gas (RNG) sales, alongside planning for future opportunities with the upcoming Cummins X15N engine. In the fourth quarter of 2024, Clean Energy sold 62.0 million gallons of RNG, representing an 8.8% rise from the same period the year before. Over the full year, the company achieved a 4.9% increase in RNG sales, totaling 236.7 million gallons, according to details shared at their investor relations site. This growth comes as Clean Energy gears up for the anticipated end-of-2024 launch of the Cummins X15N, a 15-liter natural gas engine specifically designed for heavy-duty trucks. The company predicts that more than 25 fleets will adopt this engine in 2025, contributing to an estimated fuel usage of 3 to 5 million gallons. To support this rollout, Clean Energy plans to spend up to $104 million in developing anaerobic digestion RNG production facilities, which will supply the necessary fuel for these engines. Clean Energy Fuels is emphasizing its strategy to drive further adoption of RNG and capitalize on the introduction of the Cummins X15N to strengthen sustainable transportation efforts. This initiative is part of a broader push to integrate cleaner fuel technologies and build a robust infrastructure to meet the evolving needs of the transport sector.

Altice USA Sets Sights on $3.4 Billion Adjusted EBITDA by 2025

Altice USA Sets Sights on $3.4 Billion Adjusted EBITDA by 2025

18 minutes agoATUS

Altice USA has revealed ambitious financial goals for 2025, targeting an adjusted EBITDA of $3.4 billion. This objective is primarily fueled by the company's expansion in its fiber and mobile sectors, marking a strategic push to bolster its offerings in high-demand areas. In 2024, Altice USA reported a revenue of $8.95 billion and an operating income of $1.68 billion. This robust financial performance sets the stage for the company's growth strategy in the coming years. According to information available on Wikipedia, these figures highlight the company's steady financial footing as it seeks to make significant gains in the fiber and mobile markets. As of May 9, 2025, Altice USA's stock is trading at $2.77 per share, a rise of 4.55% from the previous close. By aligning its strategy with growing industry trends that prioritize high-speed internet and mobile connectivity, Altice USA hopes to strengthen its position in these competitive markets.

Trinseo Unveils Restructuring Initiatives to Boost Profitability

Trinseo Unveils Restructuring Initiatives to Boost Profitability

33 minutes agoTSE

Trinseo has announced new strategies focused on improving profitability and operational efficiency, including the consolidation of its business units. As of October 1, 2024, the company will merge its Engineered Materials, Plastics Solutions, and Polystyrene business segments. This restructuring is expected to save about $30 million annually, with $25 million anticipated in 2025 and full savings realized by the end of 2026, according to Morningstar. In addition to restructuring, Trinseo plans to cease virgin polycarbonate production at its Stade, Germany facility by January 2025, seeking to enhance annual profitability by $15 million to $20 million compared to current production costs. Financially, the company reported a third-quarter net loss of $87 million on net sales of $868 million, slightly down by 1% from the previous year. However, adjusted EBITDA rose by $25 million year-over-year to reach $66 million, as reported by StockTitan. Looking ahead to the fourth quarter of 2024, Trinseo anticipates a net loss between $81 million and $71 million, with adjusted EBITDA projected between $40 million and $50 million. Despite recent losses, the company maintains a robust liquidity position, holding $167 million in cash, with $177 million available, totaling $344 million to support these strategic shifts. These initiatives signal Trinseo's dedication to refining efficiency in response to market challenges.

AMN Healthcare Projects Strong Q2 2025 Revenue Growth

AMN Healthcare Projects Strong Q2 2025 Revenue Growth

48 minutes agoAMN

AMN Healthcare Services Inc. has set its sights on a promising financial outlook for the second quarter of 2025, projecting revenue between $645 million and $660 million. This optimistic forecast comes amid anticipated growth in key areas of the company's operations. The healthcare staffing firm expects to see significant contributions from its locum tenens services, which are projected to bolster revenue. Similarly, AMN predicts further expansion in its allied staffing services. However, the company acknowledges challenges in its travel nurse segment, which is expected to decline and impact revenue mix. Additionally, its technology and workforce solutions segment is anticipated to experience a slight dip due to decreased demand. Despite these challenges, AMN remains focused on streamlining contingent labor costs and enhancing strategic talent solutions. Reuters reported that these projections are aligned with AMN Healthcare's broader strategy of expanding its locum tenens and allied staffing services. The company notes stable market conditions and foresees an uptick in client demand during the winter months. As for the stock market, AMN Healthcare's shares recently traded at $20.33, reflecting a slight increase from the previous close, with an intraday high of $23.49.